COIOSDeep risk insights through multi-disciplinary research across the globe
A person with a backpack on a wooden balcony overlooking golden rice terraces
Item new Peer-reviewed Added

Amyloid-targeting therapy eligibility in China narrowed by diagnosis and biomarker access

A meta-analysis estimated 39,825 Chinese adults eligible for amyloid-targeting therapy under current care, against 14.17 million without access constraints.

This systematic review estimated MCI and AD prevalence and the population potentially eligible for amyloid-targeting therapy. It pooled population-based studies from 2020 to 2026, covering 312,204 participants aged 60 and over in mainland China. Pooled prevalence was 21.21% (95% CI 17.41–25.01%) for MCI and 4.72% (95% CI 3.13–6.31%) for AD. A stepwise funnel model then applied rates of consultation, clinical diagnosis, biomarker testing and amyloid positivity. Under current conditions, 39,825 people were potentially eligible for amyloid-targeting therapy, against 14.17 million without these constraints. Most studies were of moderate quality, heterogeneity was extreme (I² 99.7–99.8%), and age-stratified evidence was limited.

Why it is interesting: The modelled eligible population falls from 14.17 million to 39,825 once current consultation, diagnosis and biomarker testing rates are applied. The gap places the main constraint on access in diagnostic pathways, not in disease prevalence.

Source
Advances in Therapy, 18 November 2026
DOI
10.1007/s12325-026-03800-3
Type
Peer-reviewed article
Design
Systematic review and random-effects meta-analysis of 27 population-based prevalence studies (n=312,204, adults 60+, searched 2020-Aug 2026) feeding a stepwise funnel model with probabilistic sensitivity analysis
Verdict
New finding
Driver
Dementia

Other drivers in Health today